Qing-yun Zhang1, Ji-wei Wang1, Jin-ming Yu2. 1. Institute of Clinical Epidemiology, Key Lab of Health Technology Assessment (Ministry of Health), School of Public Health, Fudan University, Shanghai 200032, China. 2. Institute of Clinical Epidemiology, Key Lab of Health Technology Assessment (Ministry of Health) , School of Public Health, Fudan University, Shanghai 200032, China. Email: jmy@fudan.edu.cn.
Abstract
OBJECTIVE: To evaluate the efficacy and safety of Kuntai Capsule and Estrogen for Menopausal Syndrome. METHODS: Related randomized controlled trials about Kuntai capsule and estrogen in recent 10 years were collected by various kinds of database according to strict inclusion and exclusion criteria. Valid data were extracted to conduct meta-analysis by RevMan5.0. RESULTS: A total of 196 articles were retrieved, but only 6 were finally included. Meta-analysis showed that no significant differences were observed in Kupperman score between Kuntai group and estrogen [WMD = 0.22, 95%CI (-1.14, 1.58), P > 0.05]. While E(2) level was significantly higher in estrogen group than that in Kuntai [WMD = -59.59, 95%CI(-87.35, -31.83), P < 0.01]. The incidence of adverse effects was significantly lower in Kuntai group compared to the estrogen group [RR = 0.61, 95%CI(0.45,0.83), P < 0.01]. CONCLUSION: Kuntai can improve symptoms of menopausal syndrome effectively as the same as estrogen and tends to have lower incidence of adverse effects.
OBJECTIVE: To evaluate the efficacy and safety of Kuntai Capsule and Estrogen for Menopausal Syndrome. METHODS: Related randomized controlled trials about Kuntai capsule and estrogen in recent 10 years were collected by various kinds of database according to strict inclusion and exclusion criteria. Valid data were extracted to conduct meta-analysis by RevMan5.0. RESULTS: A total of 196 articles were retrieved, but only 6 were finally included. Meta-analysis showed that no significant differences were observed in Kupperman score between Kuntai group and estrogen [WMD = 0.22, 95%CI (-1.14, 1.58), P > 0.05]. While E(2) level was significantly higher in estrogen group than that in Kuntai [WMD = -59.59, 95%CI(-87.35, -31.83), P < 0.01]. The incidence of adverse effects was significantly lower in Kuntai group compared to the estrogen group [RR = 0.61, 95%CI(0.45,0.83), P < 0.01]. CONCLUSION: Kuntai can improve symptoms of menopausal syndrome effectively as the same as estrogen and tends to have lower incidence of adverse effects.